The objective of this rollover study is to evaluate the long term (1 year) safety of a new weekly administered growth hormone preparation in adults with growth hormone deficiency who were treated with the same experimental preparation in study BPLG-005. In addition, further change in efficacy endpoints of BPLG-005 by prolonged treatment will be evaluated. Additional efficacy and safety data of the experimental preparation will be obtained from the switch-over patients.

Inclusion Criteria:

• Patients (male and female) who have completed the Visit 8 of preceding main study (BPLG-005) and are willing to continue their participation in an extension study
• If female, women of child-bearing potential who are using a reliable method of contraception and be willing to use it throughout the study. A negative urine pregnancy test at Visit 0 is required for females of child-bearing potential
• Written informed consent of the patient

Exclusion Criteria:

• Evidence of active malignancy or growth of a previously stable tumor
• Benign intracranial hypertension
• Clinically significant respiratory, cardiac, hepatic, renal, neuromuscular disease
• Non-compliance with medications, un-cooperativeness or drug abuse during the BPLG-005 study
• Patients who are not able to comply with the study protocol for any reason